Chemotherapy: Open Access
Open Access

Abstract

Targeting the PI3K/AKT Pathway for the Treatment of the Gastric Cancer

Yuyan Liu, Sunrong Sun, Juanjuan Li and De-Hua Yu,

Gastric Cancer (GC) is the fourth most common malignancy and the second leading cause of cancer deaths, accounting for 10% of global cancer mortalities. Despite the progress made in recent years, the prognosis for patients with advanced-stage GC remains poor. In the metastatic setting, chemotherapy is the primary choice for palliative therapy and results in Objective Response Rates (ORRs) of only 20-40% and median Overall Survivals (OSs) of 8–10 months. Emerging evidence suggests that the aberrant activation of phosphatidylinositol 3-kinase (PI3K)/AKT signaling is one of the most common molecular events involved in the resistance to current systemic therapies for GC.A number of small molecule inhibitors targeting the PI3K/AKT pathway are currently under clinical evaluation for the treatment of various malignancies, including GC. In this paper, we review the current clinical practice and discuss the potential use of inhibitors targeting the PI3K/AKT pathway, either alone or in combination with current therapies for the treatment of advanced GC.

Published Date: 2021-04-27; Received Date: 2021-04-06